Bacterial lipopolysaccharide activates HIV long terminal repeat through Toll-like receptor 4

J Immunol. 2001 Feb 15;166(4):2342-7. doi: 10.4049/jimmunol.166.4.2342.

Abstract

In HIV-infected patients, concurrent infections with bacteria and viruses are known to induce HIV replication as assessed by increases in plasma HIV RNA levels. In the present study, we determined the cell surface receptor and molecular mechanisms of enterobacterial LPS-induced HIV transcription. Human dermal microvessel endothelial cells (HMEC) were transfected with an HIV-long terminal repeat (LTR)-luciferase construct and subsequently stimulated with purified bacterial LPS. Our studies demonstrate that human Toll-like receptor 4 (TLR4) mediates LPS-induced NF-kappaB and HIV-LTR activation in HMEC through IL-1 signaling molecules, namely myeloid differentiation protein, IL-1R-associated kinase, TNFR-associated factor, and NF-kappaB-inducing kinase. Cotransfection of HMEC with HIV-LTR-luciferase and TLR4 cDNA from LPS-hyporesponsive C3H/HeJ mice abrogates LPS-induced HIV transcription as does the use of dominant-negative mutants of the IL-1 signaling molecules. Transfection of HMEC with an HIV-LTR-mutant that lacks the NF-kappaB binding site or pretreatment of cells with chemical inhibitors of the NF-kappaB pathway also blocked LPS-induced HIV-LTR transactivation. These data support the conclusion that TLR4 mediates enterobacterial LPS-induced HIV transcription via IL-1 signaling molecules and NF-kappaB activation plays an important role in HIV-LTR transactivation.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cell Line, Transformed
  • Chromones / pharmacology
  • Drosophila Proteins*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / immunology
  • Endothelium, Vascular / metabolism
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology
  • HIV Long Terminal Repeat / drug effects
  • HIV Long Terminal Repeat / immunology*
  • Humans
  • Imidazoles / pharmacology
  • Interleukin-1 / physiology
  • Lipopolysaccharides / antagonists & inhibitors
  • Lipopolysaccharides / pharmacology*
  • Luciferases / antagonists & inhibitors
  • Luciferases / biosynthesis
  • Luciferases / genetics
  • Membrane Glycoproteins / physiology*
  • Mice
  • Mice, Inbred C3H
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / physiology
  • Morpholines / pharmacology
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Phosphatidylinositol 3-Kinases / physiology
  • Phosphoinositide-3 Kinase Inhibitors
  • Prostaglandin D2 / analogs & derivatives
  • Prostaglandin D2 / pharmacology
  • Pyridines / pharmacology
  • Receptors, Cell Surface / physiology*
  • Signal Transduction / immunology*
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • Transcriptional Activation / drug effects
  • Transcriptional Activation / immunology*
  • p38 Mitogen-Activated Protein Kinases

Substances

  • 15-deoxy-delta(12,14)-prostaglandin J2
  • Chromones
  • Drosophila Proteins
  • Enzyme Inhibitors
  • Imidazoles
  • Interleukin-1
  • Lipopolysaccharides
  • Membrane Glycoproteins
  • Morpholines
  • NF-kappa B
  • Phosphoinositide-3 Kinase Inhibitors
  • Pyridines
  • Receptors, Cell Surface
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Toll-Like Receptors
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Luciferases
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580
  • Prostaglandin D2